Between May 18 and September 8, 2026, Fintent flagged 43 healthcare and life sciences transactions before they were announced. The median first detectable M&A signal in that set landed 22.9 months ahead of the announcement — Merck KGaA's $11.3 billion agreement to buy Bio-Techne (emdgroup.com), Vertex's roughly $10 billion acquisition of Crinetics (crinetics.com), GSK's $10.6 billion deal for Nuvalent (gsk.com), Dassault Systèmes buying ArisGlobal (arisglobal.com), Garmin buying TrainingPeaks (garmin.com). In each case the behaviour that precedes a process was observable in 2024.
Treat 43 as a floor rather than a count. It reflects only the acquirees our firmographic data classifies inside the healthcare and life sciences universe, over a sixteen-week window of weekly prediction files; companies tagged in adjacent industries and companies we do not carry are not in it. The lead times are floors too — signal history for this cohort begins in mid-2024, so a deal announced in mid-2026 cannot show more than about 24 months of runway even if the runway was longer.
Which healthcare deals did Fintent call before they were announced?
Ten of the 43, chosen for lead time, signal richness and buyers you will recognise. "Signal detected" is the month the earliest M&A intent signal appeared against that company; "announced" is the date the transaction became public. Three of the ten round out the set at the extremes of the table: Eli Lilly's acquisition of Curevo Vaccine for up to $1.5 billion (investor.lilly.com), Tempus's roughly $1.5 billion acquisition of the genomic diagnostics business Personalis (investors.tempus.com), and The Oregon Clinic's absorption of the independent Portland primary-care practice Broadway Medical Clinic (oregonclinic.com).
| Company | Acquirer | Announced | Signal Detected | Intent Signals | Lead Time |
|---|---|---|---|---|---|
| Bio-Techne | Merck KGaA | June 25, 2026 | July 2024 | Investment bank, private equity, seller financing | ~24 months |
| Personalis | Tempus AI | July 20, 2026 | August 2024 | Investment bank, business merger, business broker | ~24 months |
| Nuvalent | GSK | June 9, 2026 | July 2024 | Investment bank, business broker | ~23 months |
| Crinetics Pharmaceuticals | Vertex Pharmaceuticals | July 6, 2026 | August 2024 | Investment bank, equity financing, company acquisition | ~23 months |
| Curevo Vaccine | Eli Lilly | May 26, 2026 | July 2024 | Equity financing, investment bank, confidential information memorandum | ~23 months |
| MatrixCare | Frazier Healthcare Partners | July 7, 2026 | August 2024 | Investment bank, seller financing, business broker | ~23 months |
| ArisGlobal | Dassault Systemes | July 23, 2026 | September 2024 | Investment bank, seller financing, business valuation | ~23 months |
| TrainingPeaks | Garmin | July 22, 2026 | September 2024 | Investment bank, M&A auction, private equity | ~23 months |
| Broadway Medical Clinic | The Oregon Clinic | June 8, 2026 | October 2024 | Investment bank, corporate law firm, M&A | ~20 months |
| Logan Regional Medical Center | LifePoint Health | March 6, 2026 (closed June 2) | July 2024 | Investment bank, equity financing, business valuation | ~20 months |
Bio-Techne to Merck KGaA — signal detected July 2024, announced June 25, 2026
Bio-Techne makes life-science reagents and instruments — proteins, antibodies, spatial biology and protein-detection systems — the picks-and-shovels layer under multi-omics and cell and gene therapy work. Merck KGaA agreed to acquire it for roughly $11.3 billion at $73 a share, framing the deal as a move to consolidate its position in spatial biology and precision diagnostics (emdgroup.com).
The signal profile is a textbook sponsor-and-banker process, and it was running two years early. Investment bank, private equity and seller financing appearing together against a listed company is not idle chatter — it is the pattern of a board testing what an asset is worth and how a transaction would be structured. Twenty-three separate M&A signals accumulated against Bio-Techne from July 2024 onward. For an adviser, a two-year runway on an $11 billion asset is not a pitch window; it is enough time to build the relationship that gets you in the room when the process is finally stood up.
Crinetics Pharmaceuticals to Vertex — signal detected August 2024, announced July 6, 2026
Crinetics develops oral small-molecule drugs for endocrine disease, with an approved acromegaly therapy and a Phase 3 candidate for congenital adrenal hyperplasia. Vertex agreed to acquire it for about $10 billion at $85 a share, buying near-term launch revenue alongside pipeline (crinetics.com).
Investment bank, equity financing and company acquisition together, twenty-three months out, is the signature of a company keeping two exits open at once. A clinical-stage biotech with a launch ahead of it can raise or it can sell, and the behaviour looks similar from the outside until quite late. That ambiguity is precisely why the signal is useful: it appears while both paths are still live, which is the only period in which an adviser can influence which one gets taken.
ArisGlobal to Dassault Systemes — signal detected September 2024, announced July 23, 2026
ArisGlobal runs an AI-native compliance platform for pharmacovigilance, regulatory and medical-affairs functions, serving more than 200 biopharma customers. Dassault Systemes agreed to acquire it for roughly $1.8 billion in cash plus up to $200 million in milestones, positioning it as the regulated-operations layer of a platform that already spans discovery and clinical R&D (arisglobal.com).
The signal profile here reads sponsor-exit rather than strategic courtship: investment bank, seller financing and business valuation, with Merrill Lynch, Water Street and Insight Partners in the deal-maker signal. Fourteen M&A signals accumulated from September 2024. Seller financing appearing early in a sponsor-owned software asset usually means the valuation gap is being worked before the bankers go wide — a detail that tells an adviser what the process will actually turn on.
MatrixCare to Frazier Healthcare Partners — signal detected August 2024, announced July 7, 2026
MatrixCare is cloud EHR and care-management software for skilled nursing, senior living, home health and hospice providers. Frazier Healthcare Partners agreed to acquire it from ResMed, which classified the business as non-core under its 2030 portfolio strategy (businesswire.com).
Corporate divestitures are the hardest transactions to see coming and the easiest to see in this data, because a carve-out generates preparation behaviour inside the parent long before it generates a press release. Investment bank, seller financing and business broker signals ran against MatrixCare from August 2024 — roughly a year before ResMed publicly framed the asset as non-core. For a sponsor or a strategic hunting carve-outs, that is the difference between competing in a banked process and having a conversation with the parent first.
TrainingPeaks to Garmin — signal detected September 2024, announced July 22, 2026
TrainingPeaks is a coaching and training-analytics platform for endurance athletes and their coaches. Garmin acquired it alongside sister platform TrainHeroic, extending a hardware ecosystem into the software and coaching layer that sits on top of it (garmin.com).
Investment bank, M&A auction and private equity appearing together is the least ambiguous profile in this table — an auction signal is not something a company generates by accident. It ran twenty-three months before announcement. The wider point is the buyer: Garmin is not a healthcare acquirer, and a coverage universe restricted to healthcare strategics and healthcare sponsors would never have modelled this outcome. Health and wellness assets increasingly clear to consumer and technology balance sheets, and the intent signal shows up regardless of which industry the eventual buyer sits in.
Where were those deals actually coming from?
Overwhelmingly from the product and platform end of healthcare, not from care delivery: 16 of the 43 predicted transactions were biotechnology research or pharmaceutical manufacturing companies — 37% of the deals from a sub-sector that accounts for 2,932 of the 83,200 companies in our healthcare cohort, or 3.5%. Five of the ten deals in the table above sit in that one sub-sector. Two more — ArisGlobal and MatrixCare — sit in Healthcare IT & Software. One, TrainingPeaks, sits in Health & Wellness Services.
That concentration is not an accident of which deals we chose to feature. It matches the sub-sector map: the five sub-sectors showing the most deal-preparation behaviour relative to the sector baseline are Digital & Marketing Agencies and Biotechnology & Pharmaceuticals at 2.02x, Therapy & Rehabilitation Services at 1.52x, Healthcare IT & Software at 1.45x and Health & Wellness Services at 1.42x.
The external record points the same way. Reuters put Q1 2026 biopharma M&A value at $84 billion against $44.4 billion a year earlier, with more than $300 billion of sector revenue facing loss of exclusivity inside five years (reuters.com) — a deadline-driven bid rather than a cyclical one. In health IT, Healthcare Growth Partners counted 121 announced transactions in Q2 2026 with revenue multiples recovering to 4.7x from a 3.7x April low (hitconsultant.net). Neither of those is a story about hospitals.
So what: if your healthcare coverage model is organised by care setting, reorganise it around what the business actually sells. The propensity spread inside this sector runs 2.02x to 0.63x while the sector index itself sits at 0.98x — parity. Everything worth trading on is internal to the sector.
| Sub-sector | Companies | M&A Propensity | CapRaise Propensity | 8Q Trend | Read |
|---|---|---|---|---|---|
| Digital & Marketing Agencies | 1,071 | 2.02x | 0.76x | Rising | Hot — evidence thin |
| Biotechnology & Pharmaceuticals | 2,932 | 2.02x | 1.68x | Easing off peak | Hot |
| Therapy & Rehabilitation Services | 2,202 | 1.52x | 1.44x | Dipped, recovering | Sponsor exit cycle |
| Healthcare IT & Software | 2,638 | 1.45x | 1.42x | Rising | Hot |
| Health & Wellness Services | 4,496 | 1.42x | 1.35x | Dipped, recovering | Strategic buyer bid |
Top 5 sub-sectors by M&A Propensity versus the sector baseline, September 2026. Sub-sectors with fewer than 1,000 tracked companies are excluded as low-signal. CapRaise Propensity is shown for completeness.
So why did two of them come from the bottom of the table?
Because a propensity index is a base rate, not a veto — and the coolest sub-sector in healthcare is also the largest. Broadway Medical Clinic sits in Healthcare Providers, which reads 0.84x. Logan Regional Medical Center sits in Healthcare Facilities & Clinics, which reads 0.66x on 27,627 companies, the biggest cohort in the sector by a wide margin. A weak base rate applied to 27,627 companies still produces transactions; it just produces fewer of them per company covered.
The arithmetic across the full prediction set makes the point cleanly. Care delivery — hospitals and health care plus medical practices, as classified in our firmographic data — produced 6 of the 43 predicted transactions, or 14%, while Healthcare Facilities & Clinics and Healthcare Providers together account for 30,999 of the 83,200 companies in the cohort, or 37%. More than a third of the population, one-seventh of the deals.
The reason is regulatory, and it is well documented. STAT, citing PitchBook, reports private-equity physician-practice-management deals falling from a 2021 peak of 851 to 105 in the first half of 2026 (statnews.com), with more than a dozen states adding healthcare private-equity oversight in the past year; Stateline counts at least 25 states that have proposed or passed transaction review legislation (stateline.org). Fierce Healthcare projects 674 healthcare services private-equity deals for 2026, the lowest since 2017 (fiercehealthcare.com).
Worth naming the counter-evidence rather than hiding it: hospital M&A did rebound in early 2026, with 22 transactions in Q1, the strongest first quarter since 2020 (healthleadersmedia.com). That rebound is concentrated in large system-level mergers and divestitures. It does not lift the base rate for 27,627 mid-sized facilities, which is what our index measures — and the fact that Logan Regional came to us through a multi-hospital portfolio sale by LifePoint rather than through an independent process is itself an illustration of the mechanism (lifepointhealth.net).
So what: do not stop covering the cool sub-sectors, and do not cover them the same way. In the top five, the propensity read earns broad outreach. In the bottom five, work from named signals only — the individual company scoring high despite a weak cohort is exactly the name your competitors' sector screens will filter out.
| Sub-sector | Companies | M&A Propensity | CapRaise Propensity | 8Q Trend | Read |
|---|---|---|---|---|---|
| Education & Professional Associations | 1,376 | 0.63x | 0.92x | Falling | Cold — evidence thin |
| Healthcare Facilities & Clinics | 27,627 | 0.66x | 0.55x | Rising off a low base | Cold, large-cap decoupled |
| Industrial Equipment & Tools | 1,351 | 0.74x | 1.17x | Falling, then flat | Cold — tariff drag |
| Pharmacy & Pharmaceutical Services | 1,123 | 0.79x | 1.05x | Falling | Distress, not sale processes |
| Healthcare Providers | 3,372 | 0.84x | 0.98x | Falling | Regulatory overhang |
Bottom 5 sub-sectors by M&A Propensity versus the sector baseline, September 2026. Sub-sectors with fewer than 1,000 tracked companies are excluded as low-signal. CapRaise Propensity is shown for completeness.
What are we tracking right now?
These ten are a sample. 431 middle-market healthcare and life sciences companies scored 50 or higher on Fintent's M&A intent score in the last month — drawn from a tracked universe of roughly 98,600 US companies with 25 to 1,000 employees across the healthcare and life sciences industry groupings. By count, the largest contributors are hospitals and health care (92), health and human services (82), health, wellness and fitness (73), medical practices (64) and biotechnology and pharmaceuticals (43). That distribution follows cohort size rather than propensity, which is the point of running both numbers: the propensity index tells you where a company is unusually likely to be preparing relative to its peers, and this count tells you how many names are actually on the board today.
For the reader who wants to audit the claim rather than take it on faith.
How does Fintent predict deals before they're announced?
Fintent reads company-level financial-intent signals — the observable traces of an investment bank being engaged, a corporate law firm being retained, a valuation being run, seller financing or an earn-out being structured, a confidential information memorandum circulating, an auction being organised — then scores each signal, dates it, and attaches it to the company. None of these is an announcement. All of them are things that happen before one.
Each signal carries a date, which is what makes lead time measurable rather than anecdotal. Across the 43 healthcare and life sciences transactions in this window, the median first detectable M&A signal appeared 22.9 months before the deal became public. Two caveats we would rather state than have you discover: the count of 43 is a floor, because it captures only acquirees our firmographic data classifies inside this sector; and the lead times are floors too, because signal history for this cohort begins in mid-2024.
The signal profile is often more useful than the score. Investment bank alone is ambiguous. Investment bank plus corporate law firm plus leveraged buyout is a sponsor-driven process standing up. Investment bank plus seller financing plus business valuation, inside a sponsor-owned asset, is a valuation gap being worked before the bankers go wide. Reading the combination is how an adviser decides whether to make a call this quarter or next year.
Frequently asked questions
How many healthcare acquisitions did Fintent predict in 2026?
Fintent flagged 43 healthcare and life sciences transactions between May 18 and September 8, 2026, across sixteen weeks of prediction files. That figure is a floor rather than a total, because it counts only acquirees our firmographic data classifies inside the healthcare and life sciences universe.
How far in advance does Fintent detect M&A intent in healthcare?
The median first detectable M&A signal across the 43 predicted healthcare transactions appeared 22.9 months before announcement. Individual lead times in the featured set run from about 20 months for Logan Regional Medical Center and Broadway Medical Clinic to about 24 months for Bio-Techne and Personalis.
What counts as a financial-intent signal?
Observable behaviour that precedes a transaction: an investment bank engaged, a corporate law firm retained, a business valuation run, seller financing or an earn-out structured, a confidential information memorandum in circulation, an M&A auction organised, private-equity involvement surfacing. Each signal is scored and dated, so lead time is measurable rather than estimated.
Which healthcare sub-sectors produced the most predicted deals?
Biotechnology and pharmaceuticals produced 16 of the 43 predicted transactions — 37% of the deals from a sub-sector representing 3.5% of the tracked cohort. Care delivery, meaning hospitals and physician practices, produced 6 of 43 despite accounting for roughly 37% of the companies in the sector.
Why did some predicted deals come from low-propensity sub-sectors?
Because propensity is a base rate rather than a veto. Healthcare Facilities & Clinics reads 0.66x but contains 27,627 companies, the largest cohort in the sector, so it still produces transactions in absolute terms. In cool sub-sectors the right approach is to work from named company signals rather than broad outreach.
Does a high M&A intent score mean a company is definitely selling?
No. A high score means a company is showing more of the observable behaviour that precedes a transaction than its peers are. Some of those processes end in a sale, some in a financing round, and some in nothing at all. The signal identifies where to spend coverage time, not what the outcome will be.
How do I get the current list of high-scoring healthcare companies?
Book a demo with Fintent and we will share the 50 highest-scoring middle-market healthcare and life sciences companies from the current month at no charge, with the intent topics and signal dates behind each one, so you can judge the read against your own coverage universe.
Sources
- Merck KGaA agreement to acquire Bio-Techne — Merck KGaA (EMD Group), June 25, 2026 — Roughly $11.3bn at $73 per share; spatial biology and precision diagnostics rationale.
- Vertex to Acquire Crinetics Pharmaceuticals — Crinetics Pharmaceuticals, July 6, 2026 — Approximately $10bn at $85 per share; endocrine-disease portfolio.
- GSK enters agreement to acquire Nuvalent, Inc. — GSK, June 9, 2026 — Approximately $10.6bn precision-oncology acquisition.
- Lilly announces three acquisitions to build infectious disease portfolio — Eli Lilly, May 26, 2026 — Includes Curevo Vaccine for up to $1.5bn.
- Tempus to acquire Personalis, more tightly integrating molecular residual disease testing — Tempus AI, July 20, 2026 — Approximately $1.5bn genomic diagnostics acquisition.
- Dassault Systemes to acquire ArisGlobal — ArisGlobal, July 23, 2026 — Roughly $1.8bn cash plus up to $200m in milestones.
- Frazier Healthcare Partners Announces Definitive Agreement to Acquire MatrixCare — BusinessWire, July 7, 2026 — Carve-out from ResMed under its 2030 portfolio strategy.
- Garmin acquires TrainingPeaks and TrainHeroic — Garmin, July 22, 2026 — Consumer-technology buyer acquiring a health and wellness software platform.
- LifePoint Health acquires eight hospitals from ScionHealth — LifePoint Health, June 2, 2026 (signed March 6, 2026) — Logan Regional Medical Center was part of an eight-hospital portfolio transaction.
- Broadway Medical Clinic joins The Oregon Clinic — The Oregon Clinic, June 8, 2026 — Independent Portland primary-care practice absorbed by a larger specialty group.
- Big Pharma M&A set for mega year as patent expiries drive deal urgency — Reuters, May 1, 2026 — Q1 2026 biopharma M&A value of $84bn against $44.4bn a year earlier; over $300bn of revenue facing loss of exclusivity.
- HGP July 2026 Health IT Market Review: Key Valuations and M&A Benchmarks — HIT Consultant (Healthcare Growth Partners data), July 22, 2026 — 121 announced health IT transactions in Q2 2026; revenue multiples recovering to 4.7x.
- Private equity takeovers of physician groups down by half in 2026 — STAT News (PitchBook data), August 17, 2026 — Physician-practice-management deals falling from 851 in 2021 to 105 in H1 2026.
- As states tighten oversight, private equity's healthcare deals decline — Stateline, August 25, 2026 — At least 25 states have proposed or passed healthcare transaction review legislation.
- Projected healthcare services deal count to be lowest since 2017, PitchBook finds — Fierce Healthcare, August 19, 2026 — 674 projected healthcare services private-equity deals for 2026.
- From Distressed to Divestitures: Hospital M&A Roars Back in Q1 After Slow 2025 — HealthLeaders Media, 2026 — 22 hospital transactions in Q1 2026, the strongest first quarter since 2020.
431 middle-market healthcare and life sciences companies are scoring 50 or higher on M&A intent right now. Book a demo and we'll send you the top 50, free.
431 middle-market healthcare and life sciences companies are scoring 50 or higher on M&A intent right now. Book a demo and we'll send you the top 50, free.